Teva unveils long-term growth strategy, targets $6B-$7B innovative medicines revenue by 2030

Teva Pharmaceuticals unveiled a long-term growth strategy targeting $6 billion to $7 billion in innovative medicines revenue by 2030.

Detected & updated continuously · Source: Nebula